Furthermore, in vivo experiments with prostate cancer have shown that the extent of PC-3-bone metastases depends on the bioavailability of NALCN in prostate cancer cells and that its expression in these cells increases with prostate cancer aggressiveness [23]. This evidence concerns the gene NALCN and prostate carcinoma.